BioStock: The future of obesity treatment - Iconovo develops intranasal semaglutide
Iconovo has initiated the development of an intranasally inhaled and reformulated version of semaglutide to treat obesity. By utilizing its inhalation-driven intranasal device, ICOone Nasal, the company aims to create a more user-friendly treatment than current semaglutide injections. The goal is to achieve preclinical proof-of-concept and enter into a licensing agreement, according to CEO Johan Wäborg in an interview with BioStock.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se